Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

NCT00939809 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT00939809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00939809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2009
Completion date
Not reported
Enrollment
31 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube carcinoma, malignant ovarian mixed epithelial tumor, ovarian brenner tumor, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian mucinous cystadenocarcinoma, ovarian serous cystadenocarcinoma, primary peritoneal carcinoma, recurrent ovarian carcinoma, undifferentiated ovarian carcinoma